---
title: "Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Dosing and administration questions"
description: "Dosing and administration questions on Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Treatment duration, and Treatment combinations. Questions: What is the Verzenio dose for early breast cancer? How long is Verzenio taken for early breast cancer? Do premenopausal women and men on Verzenio plus an aromatase inhibitor need a GnRH agonist? How is the Verzenio dose reduced for side effects? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Dosing and administration questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Verzenio](https://uspl.lilly.com/verzenio/verzenio.html#pi)

Dosing and administration questions that apply to every indication of Verzenio are on [Verzenio (abemaciclib), all indications: Dosing and administration](https://www.evicenter.com/medical-information/verzenio/dosing-and-administration).

## Dosing

<a id="verzenio-dose"></a>

### What is the Verzenio dose for early breast cancer?

> “The recommended dosage of VERZENIO is 150 mg orally twice daily.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=The%20recommended%20dosage%20of%20VERZENIO%20is%20150%20mg%20orally%20twice%20daily.)

> “When used in combination with ET for HR+, HER2–, high-risk* EBC, the recommended dose of Verzenio is 150 mg taken orally twice daily, continued until completion of two years of treatment or until disease recurrence, or unacceptable toxicity.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=When%20used%20in%20combination%20with,disease%20recurrence%2C%20or%20unacceptable%20toxicity.)

> “Refer to the Prescribing Information for the recommended dose of the fulvestrant, tamoxifen, imlunestrant or aromatase inhibitor being used.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Refer%20to%20the%20Prescribing%20Information,or%20aromatase%20inhibitor%20being%20used.)

<a id="verzenio-dose-reductions"></a>

### How is the Verzenio dose reduced for side effects?

> “The recommended VERZENIO dose reductions for adverse reactions are provided in Table 1. Permanently discontinue VERZENIO for patients unable to tolerate 50 mg twice daily.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=The%20recommended%20VERZENIO%20dose%20reductions,tolerate%2050%20mg%20twice%20daily.)

> “Table 1: Recommended VERZENIO Dose Reductions for Adverse Reactions
> Dosage Level	VERZENIO Dose in
> Combination with Fulvestrant, Tamoxifen, Imlunestrant or an Aromatase Inhibitor	VERZENIO Dose
> for Monotherapy
> Recommended starting dosage	150 mg twice daily	200 mg twice daily
> First dosage reduction	100 mg twice daily	150 mg twice daily
> Second dosage reduction	50 mg twice daily	100 mg twice daily
> Third dosage reduction	not applicable	50 mg twice daily”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Table%201%3A%20Recommended%20VERZENIO%20Dose,50%20mg%20twice%20daily)

> “If necessary, reduce Verzenio by 50 mg at a time<sup>1</sup>
> Discontinue Verzenio for patients unable to tolerate 50 mg twice daily<sup>1</sup>”

Source: [VERZENIO: Dosing | HCP Dosing, captured 2026-11-14](https://verzenio.lilly.com/hcp/dosing#:~:text=If%20necessary%2C%20reduce%20Verzenio%20by,to%20tolerate%2050%20mg%20twice)

Note: For early breast cancer, Verzenio is given in combination with endocrine therapy (tamoxifen or an aromatase inhibitor), the second column of Table 1. The monotherapy column applies to an advanced or metastatic breast cancer indication (section 1.2 of the Prescribing Information).

## Treatment duration

<a id="verzenio-treatment-duration"></a>

### How long is Verzenio taken for early breast cancer?

> “For early breast cancer, continue VERZENIO until completion of 2 years of treatment or until disease recurrence, or unacceptable toxicity.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=For%20early%20breast%20cancer%2C%20continue,disease%20recurrence%2C%20or%20unacceptable%20toxicity.)

> “After the end of the study treatment period, standard adjuvant endocrine therapy was continued for a duration of at least 5 years if deemed medically appropriate.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=After%20the%20end%20of%20the,years%20if%20deemed%20medically%20appropriate.)

Note: The second passage describes the monarchE trial in the Clinical Studies section of the Prescribing Information.

## Treatment combinations

<a id="verzenio-gnrh-agonist"></a>

### Do premenopausal women and men on Verzenio plus an aromatase inhibitor need a GnRH agonist?

> “For premenopausal and perimenopausal women and men treated with VERZENIO in combination with an aromatase inhibitor, imlunestrant, or fulvestrant should be treated with a gonadotropin-releasing hormone agonist (GnRH) according to current clinical practice standards.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=For%20premenopausal%20and%20perimenopausal%20women,to%20current%20clinical%20practice%20standards.)

> “The following should receive a gonadotropin-releasing hormone agonist (GnRH) according to current clinical practice standards:<sup>1</sup>
>
> Pre/perimenopausal women treated with Verzenio plus an AI or fulvestrant
> Men treated with Verzenio plus an AI”

Source: [VERZENIO: Dosing | HCP Dosing, captured 2026-11-14](https://verzenio.lilly.com/hcp/dosing#:~:text=The%20following%20should%20receive%20a,Men%20treated%20with%20Verzenio%20plus%20an%20AI)

## Related pages
- [Medical information: Verzenio (abemaciclib): HR-positive HER2-negative early breast cancer](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/drug-interactions)
- [Guidelines](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/guidelines)
